FBTA-05

N/A

Report date: 2026/03/19 16:46:19

Base Information

Drug NameFBTA-05

Drug Alias NameLymphomunFBTA-05Bi-20

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3CD20-directed cytolytic effectsAnti-CD20

TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD20

Therapy Area/IndicationsLeukemiaHematopoietic stem cell transplantation (HSCT)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTrion Research

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTechnical University Of Munich

Active IndicationsN/A

Inactive IndicationsLeukemiaHematopoietic stem cell transplantation (HSCT)

Other Information

ATC CodeN/A